Building a Drug Repurposing Network (DR3N) for the CTSA Consortium:

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

Challenges in new drug discovery in South Asia
The Statisticians Role in Pharmaceutical Development
An Academic Model to Bridge the Valley of Death April 17, 2009 Scott Weir, PharmD, PhD Institute for Advancing Medical Innovation University of Kansas.
Quality by Design: A Challenge to the Pharma Industry CAMP Member Companies March 2002 CAMP.
Skin Care and Science in Harmony Concert has discovered a novel dermatological ingredient, MDI 101, that improves the health of the skin. This discovery.
Creating action with information: The Rare Disease Community Cary O. Harding, MD Department of Molecular & Medical Genetics.
Going Beyond the Current Regulatory and Incentives Frameworks A new proposal to foster greater orphan drug development 1.
ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH Anantha Shekhar MD, PhD Indiana University School of Medicine Indiana Clinical and.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
Translational Medicine Turning Basic Research into Medicines and Treatments.
Knowledge Commons: The Case of the Biopharmaceutical Industry Arti K. Rai Duke Law School.
Nanotechnology in Drug Discovery- Development and Delivery
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Stages of drug development
July 2015 PRABHAVATHI FERNANDES, PhD Founder, President and CEO How the PATH Act Can Rejuvenate Antibiotic R & D.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Pharmaceutical Epistemology Jim Golden, Ph.D. Global Lead, Healthcare Data Analytics Accenture
I MPACT OF P HARMACOGENOMICS ON THE P HARMACEUTICAL I NDUSTRY Viktoriya Buchko American Institute of Chemical Engineers August 6, 2008.
February 2008 William Petros, Pharm.D., FCCP
SOLVING THE GLOBAL MEDICAL CRISIS THROUGH SOCIAL FINANCING Rediscovery Research Social Impact Bonds First Friday Networking Group August 1, 2014 Dr. Bruce.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.
Clinical Trials Amir Zarrinhaghighi
Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.
The Innovative Medicines Initiative A winning case for Joint Technology Initiative Status.
Activities at Academic Research Centers: Identifying Present Activities and Future Opportunities ICORD V February 24, 2009 Jim Cloyd, PharmD Lawrence Weaver.
More than 90% compounds entering clinical trials fail to demonstrate safety and efficacy in human, despite evidence of safety and effectiveness in pre-
Developing medicines for the future and why it is challenging Angela Milne.
Biotechnology/Chemical Practice Committee Educational Session AIPLA 2012 Annual Meeting Oct. 25, 2012.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
The pharmaceutical R&D process
Reducing bottlenecks: Rare-purposing™ Action Duchenne, November 07, 2015 David Cavalla, CSO, Healx.
SEEK is a drug-discovery group that uses a pioneering scientific and commercially-driven approach to create breakthrough medicines which address major.
1 Impediments to Early Initiation of Pediatric Studies in a Clinical Oncology Drug Development Program A Large Pharmaceutical Company Perspective  Corporate.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.
FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.
Inventions Research & Development (R&D) in Pharmaceuticals DISCOVERY Enzymes, receptors, & genetics, DEVELOPMENT Safety, quality and efficacy tests PRODUCTION.
ANALGESIC, ANESTHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTTION) Public-Private Partnership WITH.
Bridging Biomedical Research
REPURPOSING - SOCIAL IMPACT BONDS FOR MEDICINE
Industry Perspective: Expanded Access Programs
Clinical Trials — A Closer Look
The Many Careers of Pharmacy
A journey through drug discovery The life cycle of a new medicine
Clinical Trials Medical Interventions
Gestora brasileiro focada exclusivamente na área da saúde.
SPARC – Washington University LEAP Inventor Challenge Program RFP
ECMCs – Where Do We Fit In?
From Bench to Clinical Applications: Money Talks
Non For Profit Model for Rare Disease Therapy Development
Clinical Trials.
New Targets, New Modalities, New Challenges – The Inconvenient Path of Human Genetics in Drug Discovery Enabling Precision Medicine: The Role of Genetics.
Innovation & the Pharmaceutical Research & Development Industry
Innovative Medicines Initiative:
Clinical and Translational Science Awards Program
Suzanne M. Sensabaugh, MS, MBA
Drug Design and Drug Discovery
Pediatric Clinical investigator training workshop
A Real World Application of the Scientific Method
Pharmaceuticals Industry
Center for Clinical and Translational Science
Presentation transcript:

Building a Drug Repurposing Network (DR3N) for the CTSA Consortium: Inspiration: Ovarian Cancer Collaboration Drug Repurposing: What and Why Harnessing The Power of Collaboration DR3N: The Three R’s Drug Rescue for stalled Pharma products Drug Repurposing based on experimental or computational evidence Drugs for Repositioning based on off-label indications Clinical & Translational Science Center CTSC

Inspiration: Ovarian Cancer Drug Repurposing Concept: GTPases/Receptor Traffic Screen: Sklar Multiplex/NSAIDS Cheminformatics: Oprea Ketorolac Retrospective Trial: Cook Pain Treatment/Survival Cells/Animals: Mechanism (R-enantiomer) Prospective Trial: Muller Hits Target Outcomes: Pubs, Patents, Trials, $ Wandinger-Ness Hudson

Approved drugs and devices WHY REPURPOSING? > 6,000+ Rare diseases > 100,000,000 people 1,000s Approved drugs and devices 1 2 2 Success rate of 10-30% demonstrating clinical benefit for patients based on Cures Within Reach past success rate (13 successes from 50 clinical trials). Success considered when clinical results proved the repurposed therapy works and are robust enough for physicians to use to prescribe off label OR when a project moves to a phase II/III trial on the way to commercialization. There is other support for this success rate. Repurposing generic drugs is much akin to moving a NME from phase II to phase III, since both are already proven safe for human use and have some clinical anecdotal success. Estimates of success rates for molecules moving from phase II to phase III range from 13%-32%. See this from the Institute of Medicine: “Drug repositioning or repurposing holds many appeals. Typically these drugs have been extensively profiled and studied in terms of safety, efficacy and toxicity, thereby decreasing the amount of preclinical research required. This streamlined process saves time and money, with repurposed drugs generally being approved in much shorter timelines (3-12 years) and at about 60% of the cost of typical development. While approximately 10% of new drug applications gain market approval, repurposed drugs approach approval rates near 30%, presenting a significant market-driven incentive for companies that also aligns with patient desires for new therapeutics.” Cost <$500,000 based on Cures Within Reach experience in clinical trials so far. And CWR repurposing clinical trials average is under $100,000 1=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619623/; http://bioinformatics.oxfordjournals.org/content/early/2013/06/08/bioinformatics.btt279.full.pdf 2=http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study, http://bioinformatics.oxfordjournals.org/content/early/2013/06/08/bioinformatics.btt279.full.pdf

Network Hubs/Sites: Partners & Expertise Leaders Expertise Specialization Notable UNM CMD Sklar High throughput flow cytometry; Suspension cell and molecular targets Multiplexed and multiparameter analysis BSL2/BSL3 access Repurposing trials UNM TID Oprea Drug discovery analytics; Target Prioritization for Illuminating the Druggable Genome (IDG) Databases: DrugsDB.com TargetCentral.ws IDG Knowledge Management Center KUMC/ IAMI Weir Pharmaceutics; GMP, formulation, drug delivery Public-Private Partnerships / Learning Experiences Commercialization UNC Roth Genome-wide GPCR-ome testing & de-orphanization; NIMH Psychoactive Drug Screening Program Site Bioactives/natural products; hERG/ ion channels; efflux transporters Drug limitations and removal for liabilities NCATS Simeonov Discovery Drug Libraries Drug Combinations Initiatives for drug repurposing, rare/ neglected diseases Cures Within Reach Bloom Fund raising for trials CureAccelerator website Economic Incentives Overcoming Philanthropic and Commercial Barriers Pre-competitive consortia Impact Bonds Sklar Oprea Weir Roth Simeonov Bloom

DR3N: A CTSA Resource to Speed and Facilitate New FIRST-IN-HUMAN STUDIES lsklar@salud.unm.edu